United Kingdom· GB-APID-10897811000001100
Myozyme 50mg powder for concentrate for solution for infusion vials
A alglucosidase alfa product containing alglucosidase alfa, registered in United Kingdom by Sanofi. The same ATC class is registered in 14 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Alglucosidase alfa is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AB07 (alglucosidase alfa), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Alglucosidase alfa · ATC A16AB07
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of alglucosidase alfa costs, country by country.
Normalised to the WHO defined daily dose (0.1 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Alglucosidase alfa · price per daily dose (0.1 g)
USD · FX 28 Sept 2026
- CH Switzerland$1240.40
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Alglucosidase alfa
- Manufacturer
- Sanofi
- Country
- United Kingdom (GB)
- ATC code
- A16AB07
- ATC class
- Alglucosidase alfa
- Defined daily dose
- 0.1 g, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin5030045000159
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Alglucosidase alfa in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaMYOZYMESanofi B.V., Amsterdam
- FinlandMyozymeSanofi B.V.
- IrelandMyozyme 50 mg powder for concentrate for solution for infusionSanofi B.V.
- NetherlandsMyozyme, poeder voor concentraat voor oplossing voor i.v. infusie 50 mgGenzyme Europe BV
- NorwayMyozymeSanofi B.V.
- PolandMyozymeSanofi B.V.
- BelgiumMyozyme 50 mgSanofi
- SwedenMyozyme 50 mg Pulver till koncentrat till infusionsvätska, lösningSanofi B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Myozyme
- Liechtenstein · Myozyme
- Norway · Myozyme
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/aea423ab-b1f2-43c0-839c-069f03f4ced1 GET /v1/drugs/aea423ab-b1f2-43c0-839c-069f03f4ced1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "10897811000001100",
"desc": "Myozyme 50mg powder for concentrate for solution for infusion vials (Sanofi)",
"form": "Powder for solution for infusion",
"vpid": "10900711000001103",
"source": "dmd",
"vtm_id": "774469001",
"strength": "50 mg",
"substance": "Alglucosidase alfa",
"ingredient": "Alglucosidase alfa",
"supplier_code": "9190711000001101"
}See everything about alglucosidase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.